Concepedia

Richard J. O. Barnard

RJ

Statistics

Publications

37

Citations

4.4K

H-Index

24

Active since

1994

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

United States Military Academy

University of Wisconsin–Madison

Emory University

University of Liverpool

Richard J. O. Barnard is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, virology, and hiv.

Top concepts

Publications per year

1994–2021

37

Publications

37

Monosynaptic Restriction of Transsynaptic Tracing from Single, Genetically Targeted Neurons

Ian R. Wickersham, David C. Lyon, Richard J. O. Barnard et al. · Neuron · 2007 · 1.2K citations · Full text

, , +11

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

Jeffrey L. Lennox, Edwin DeJesus, Adriano Lazzarin et al. · The Lancet · 2009 · 619 citations

, , +8

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

Joseph J. Eron, Benjamin Young, David A. Cooper et al. · The Lancet · 2010 · 312 citations

, , +10

A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals

Francesco A. Procopio, Rémi Fromentin, Deanna A. Kulpa et al. · EBioMedicine · 2015 · 262 citations · Full text

Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

Jeffrey L. Lennox, Edwin DeJesus, Daniel S Berger et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2010 · 227 citations · Full text

1–5 of 37